Trials / Recruiting
RecruitingNCT06087458
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
Phase 1/2a Dose Escalation Study of VOY-101 in Patients With Advanced Non- Neovascular Age-Related Macular Degeneration
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Perceive Biotherapeutics, Inc. · Industry
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Not accepted
Summary
The Phase 1 safety study of VOY-101 comprises of escalating dose Cohorts, followed by a Phase 2a.
Detailed description
This is a prospective, open-label, multi-center Phase 1/2a study to evaluate the safety of a single, unilateral intravitreal (IVT) injection of escalating dose levels of VOY-101 therapy in subjects with advanced non-neovascular age-related macular degeneration (AMD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | VOY-101 | VOY-101 |
Timeline
- Start date
- 2023-06-21
- Primary completion
- 2027-06-01
- Completion
- 2028-03-01
- First posted
- 2023-10-17
- Last updated
- 2025-10-15
Locations
11 sites across 3 countries: United States, Australia, Israel
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06087458. Inclusion in this directory is not an endorsement.